Skip to main content
OpenTrials
Completed

NCT Number: NCT06697821

The Number of Mesogastria Containing Metastatic Lymph Nodes Predicts Gastric Cancer Prognosis

To investigate the impact of the number of mesogastria containing metastatic lymph nodes on the prognosis of gastric cancer.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

About this study

Previous studies have established the existence of the mesogastrium, dividing it into six sections. The mesogastrium is identified during surgery and utilized in surgical practice. The aim of the present study was to further investigate its role in gastric cancer prognosis.Between January 2014 and January 2018, patients from the Tongji Hospital were included in this post-hoc analysis, including data from a randomized clinical study (DCGC01; http://www.clinicaltrials.gov, NCT01978444). Mesogastria containing metastatic lymph nodes (LNs) were referred to as metastatic mesogastria. Pathology reports were examined to assess metastases in the mesogastrium. Survival was assessed using Kaplan-Meier curves and multivariable Cox models.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • older than 18, younger than 85
  • primary gastric adenocarcinoma confirmed by preoperative pathology
  • routine blood tests, liver and kidney functions and who health status score are within the range of tolerable surgery
  • it is expected to perform radical gastrectomy through d2+cme

Exclusion criteria

  • pregnant or lactating women
  • severe mental disorder or language communication disorder
  • preoperative imaging examination or intraoperative exploration found that the patient had the following conditions: tumor involving surrounding organs requiring combined organ resection, distant organ metastasis or R0 resection could not be achieved
  • those who are not suitable for laparoscopic surgery (such as extensive adhesion caused by anterior abdominal surgery and pneumoperitoneum for various reasons).
  • concurrent malignancies at other sites
  • emergency surgery patients

Treatment and study plan

D2+CME

Procedure

Whether to perform the whole mesogastric excision

Primary outcomes

  1. Overall survival

    Time frame: Postoperative 5-year survival

    Postoperative 5-year survival

Secondary outcomes

  1. The Number of Mesogastria Containing Metastatic Lymph Nodes

    Time frame: Postoperative 5-year

    The Number of Mesogastria Containing Metastatic Lymph Nodes

Sponsors and collaborators

Lead sponsor

Jichao Qin

Other

Registry information

Important dates

Study start
2020
Primary completion
2023
Study completion
2024
First posted
Nov 20, 2024
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.